Alenson Carman's most recent trade in Prime Medicine Inc was a trade of 90,500 Stock Option (right to buy) done . Disclosure was reported to the exchange on Feb. 27, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Prime Medicine Inc | Carman Alenson | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 90,500 | 90,500 | - | - | Stock Option (right to buy) | |
| Prime Medicine Inc | Alenson Carman | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2024 | 90,498 | 90,498 | - | - | Stock Option (right to buy) | |
| Prime Medicine Inc | Carman Alenson | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Apr 2023 | 6,254 | 6,254 | - | - | Stock Option (right to buy) | |
| Prime Medicine Inc | Carman Alenson | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2023 | 90,498 | 90,498 | - | - | Stock Option (right to buy) | |
| Agios Pharmaceuticals Inc | Carman Alenson | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 61.61 per share. | 21 Jun 2021 | 1,777 | 0 (0%) | 0% | 61.6 | 109,481 | Common stock |
| Agios Pharmaceuticals Inc | Carman Alenson | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2021 | 1,777 | 3,555 | - | - | Stock option (right to buy) | |
| Agios Pharmaceuticals Inc | Carman Alenson | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 51.51 per share. | 21 Jun 2021 | 1,777 | 1,777 (0%) | 0% | 51.5 | 91,533 | Common stock |
| Agios Pharmaceuticals Inc | Carman Alenson | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 55.89 per share. | 16 Apr 2021 | 1,118 | 0 (0%) | 0% | 55.9 | 62,485 | Common stock |
| Agios Pharmaceuticals Inc | Carman Alenson | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 54.00 per share. | 15 Apr 2021 | 991 | 1,118 (0%) | 0% | 54 | 53,514 | Common stock |
| Agios Pharmaceuticals Inc | Carman Alenson | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2021 | 692 | 1,994 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Carman Alenson | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2021 | 692 | 691 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Carman Alenson | Principal Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 22 Feb 2021 | 199 | 1,795 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Carman Alenson | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2021 | 889 | 1,073 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Carman Alenson | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2021 | 889 | 1,777 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Carman Alenson | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2021 | 790 | 0 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Carman Alenson | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2021 | 790 | 1,863 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Carman Alenson | Principal Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 14 Feb 2021 | 561 | 1,302 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Carman Alenson | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 5,922 | 5,922 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Carman Alenson | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 2,961 | 2,961 | - | - | Stock option (right to buy) | |
| Agios Pharmaceuticals Inc | Carman Alenson | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Oct 2020 | 5,000 | 5,000 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Carman Alenson | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 39.93 per share. | 02 Sep 2020 | 250 | 184 (0%) | 0% | 39.9 | 9,983 | Common stock |